CD274 and non-small cell lung carcinoma: PD-L1 expression is an excellent predictive indicator; in non-small-cell lung cancer, metastatic genitourinary tumors, gastric cancer, and cervical cancer, patients with high PD-L1 expression derive more significant benefits from immunotherapy [5].